GENE Pengajuan SEC - Genetic Technologies Limited - Depositary Receipt (Common Stock)- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	529900YYKY7FRC90M744
CIK	1166272

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genetic Technologies Limited - Depositary Receipt (Common Stock)

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

December 12, 2024	EX-99.1	- END – Authorised for release by the Administrators. Exhibit 99.1 Notice of Delisting from Nasdaq and Failure to Satisfy a Continued Listing Rule or Standard. Melbourne Australia, December 12, 2024: Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) previously announced on November 20, 2024 that Ross Blakeley and Paul Harlond of FTI Consulting had been appointed as Joint and Sev
December 12, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December , 2024 Commission File Number 0-51504 GENET FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Suite 7, Level 1, 321 Chapel Street Prahran Vi
December 2, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December , 2024 Commission File Number 0-51504 GENET FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Suite 7, Level 1, 321 Chapel Street Prahran Vi
December 2, 2024	EX-99.1	- END – Authorised for release by the Voluntary Administrators of Genetic Technologies Limited. Exhibit 99.1 ASX Market Announcement Deferral relief Melbourne Australia, 29 November, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, refers to its ASX announcement of 20 November 2024 where the directors resolved to appoint Ross Blakeley and Paul Har
November 20, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November , 2024 Commission File Number 0-51504 GENET FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) Suite 7, Level 1, 321 Chapel Street Prahran Vi
November 20, 2024	EX-99.1	FTI Consulting (Australia) Pty Limited ABN 49 160 397 811 \| ACN 160 397 811 \| AFSL Authorised Representative # 001269325 Level 50, Bourke Place \| 600 Bourke Street \| Melbourne VIC 3000 \| Australia Postal Address \| GPO Box 538 \| Melbourne VIC 3001 \| A Exhibit 99.1 ASX Announcement 20 November 2024 Appointment of Voluntary Administrators to Genetic Technologies Limited (ASX Code: GTG; Nasdaq: GENE) Appointment of Voluntary Administrators Genetic Technologies Limited (Administrators Appointed) (ASX: GTG; NASDAQ: GENE) (“Genetic Technologies” or the “Company”) announces that its directors have resolved to appoint Ross Blakeley and Paul Harlond of
October 31, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October , 2024 Commission File Number 0-51504 GENETI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Aust
October 31, 2024	EX-99.1	Appendix 4C & Quarterly Business Update – September 2024 Executes Strategic Restructure – Focus on US B2B geneType and EasyDNA Exhibit 99.1 ASX Market Announcement Appendix 4C & Quarterly Business Update – September 2024 Executes Strategic Restructure – Focus on US B2B geneType and EasyDNA Melbourne, Australia, 31 October 2024: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C
October 28, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October , 2024 Commission File Number 0-51504 GENETI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Aust
October 28, 2024	EX-99.1	Genetic Technologies Receives NASDAQ Notification Regarding Minimum Stockholders’ Equity Deficiency Exhibit 99.1 Genetic Technologies Receives NASDAQ Notification Regarding Minimum Stockholders’ Equity Deficiency Melbourne Australia, October 28, 2024: Genetic Technologies Limited (NASDAQ: GENE, “Company”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced that on October 22, 2024 it received a letter from the list
October 1, 2024	EX-99.1	Corporate Governance Exhibit 99.1 Genetic Technologies Limited Corporate Governance CORPORATE GOVERNANCE STATEMENT INTRODUCTION The Company and its controlled entities together are referred to as the “Group” in this statement. Genetic Technologies Limited and its Board are committed to achieving and demonstrating the highest standards of corporate governance. The Company’s corporate governance policies and practices a
October 1, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Au
October 1, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Au
October 1, 2024	EX-99.1	Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Exhibit 99.1 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Genetic Technologies Ltd ABN Financial year ended: 17 009 212 328 30 June 2024 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on our website: https://genetype.com/investor-centre/gove
September 30, 2024	EX-13.01	CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.01 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Simon Morriss, Chief Executive Officer of th
September 30, 2024	EX-15.2	Auditor’s independence declaration (Page 1 of 1) for ASX - This page has purposefully been left blank Exhibit 15.2 Auditor’s independence declaration (Page 1 of 1) for ASX - This page has purposefully been left blank 1
September 30, 2024	EX-12.02	SARBANES-OXLEY SECTION 302(a) CERTIFICATION Exhibit 12.02 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Mark Ziirsen, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements we
September 30, 2024	EX-14.1	CODE OF ETHICS (STYLED: CODE OF CONDUCT) Exhibit 14.1 CODE OF ETHICS (STYLED: CODE OF CONDUCT) 1. Purpose This purpose of this policy is to define the Company’s Code of Business Conduct and Ethics for all Genetic Technologies Ltd (GTG) Directors and employees to adhere to. 2. Scope This policy applies to all GTG employees including the Board, Directors and Officers. 3. Responsibilities It is the responsibility of all GTG employees to hav
September 30, 2024	EX-13.02	CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.02 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Ziirsen, Chief Financial Officer of the
September 30, 2024	EX-15.3	Independent Auditors Report (Page 1 of 5) - This page has purposefully been left blank Exhibit 15.3 Independent Auditors Report (Page 1 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 2 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 3 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 4 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 5 of
September 30, 2024	EX-97.1	GENETIC TECHNOLOGIES LIMITED CLAWBACK POLICY ACKNOWLEDGEMENT FORM Exhibit 97.1 GENETIC TECHNOLOGIES LIMITED CLAWBACK POLICY ACKNOWLEDGEMENT FORM 1. Purpose. The purpose of this Genetic Technologies Limited (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comp
September 30, 2024	EX-12.01	SARBANES-OXLEY SECTION 302(a) CERTIFICATION Exhibit 12.01 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Simon Morriss, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements w
September 30, 2024	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.
September 11, 2024	EX-99.1	Genetic Technologies invited to join prestigious “CancerIQ” online platform Provides access to 45 Healthcare Systems and 250 Clinics Exhibit 99.1 ASX Market Announcement Genetic Technologies invited to join prestigious “CancerIQ” online platform Provides access to 45 Healthcare Systems and 250 Clinics Melbourne, Australia, 11 September, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company
September 11, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Au
August 28, 2024	EX-99.1	Genetic Technologies receives Nasdaq notice of noncompliance with the $1 minimum bid price requirement Exhibit 99.1 Genetic Technologies receives Nasdaq notice of noncompliance with the $1 minimum bid price requirement Melbourne Australia, August 28, 2024: Genetic Technologies Limited (NASDAQ: GENE, “Company”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, advises that it has received notification from The Nasdaq Stock Market LL
August 28, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August , 2024 Commission File Number 0-51504 GENETIC FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austr
August 15, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August , 2024 Commission File Number 0-51504 GENETIC FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August , 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austr
August 15, 2024	EX-99.1	Global launch of geneType™ on wholly owned EasyDNA platform Exhibit 99.1 ASX Market Announcement Global launch of geneType™ on wholly owned EasyDNA platform Melbourne Australia, August 15, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment p
July 31, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
July 31, 2024	EX-99.1	Appendix 4C & Quarterly Business Update – June 2024 Restructuring to focus on DTC and U.S. sales growth Exhibit 99.1 ASX Market Announcement Appendix 4C & Quarterly Business Update – June 2024 Restructuring to focus on DTC and U.S. sales growth Melbourne, Australia, 31 July 2024: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and quarterly business upd
July 26, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
July 26, 2024	EX-99.1	- END – Authorised for release by the Board of Directors. Exhibit 99.1 ASX Market Announcement Strategic restructure to focus on USA sales growth Melbourne Australia, July 26, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a ca
June 28, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
June 28, 2024	EX-99.1	Resignation of Chief Financial Officer and Company Secretary Exhibit 99.1 ASX Market Announcement Resignation of Chief Financial Officer and Company Secretary Melbourne, Australia, June 28, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, advises that Kathryn Andrews has provided her notice of resignation as Chief Financial Officer (CFO) and Compan
June 28, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
June 28, 2024	EX-99.1	EX-99.1 Exhibit 99.1
June 21, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
June 21, 2024	EX-99.1	Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27 Exhibit 99.1 ASX Market Announcement Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27 MELBOURNE, Australia – June 21, 2024 – Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webin
June 5, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australi
June 5, 2024	EX-99.1	GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test Exhibit 99.1 ASX Market Announcement GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test Melbourne, Australia, June 5, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are ex
May 29, 2024	EX-99.1	GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer Exhibit 99.1 ASX Market Announcement GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer Melbourne, Australia, May 29, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessm
May 29, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number 0-51504 GENETIC TEC FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia
May 22, 2024	CORRESP	May 22, 2024 May 22, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F.
May 20, 2024	EX-FILING FEES	Calculation of Filing Fee Table Form F-1 (Form Type) Genetic Technologies Limited (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Genetic Technologies Limited (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price(3)(4) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares, no par value, underlying Warrants to Purchase American Depositary Shares (5) Rule 457(c) 30,000,000 $ 0.
May 20, 2024	F-1	As filed with the Securities and Exchange Commission on May 17, 2024 As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.
May 6, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number 0-51504 GENETIC TEC FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia
May 6, 2024	EX-99.1	GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees. Exhibit 99.1 ASX Market Announcement GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees. Melbourne, Australia, May 6, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joi
April 30, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 30, 2024	EX-99.1	Appendix 4C & Quarterly Business Update – March 2024 Launching our most comprehensive test and expanding into new global markets Exhibit 99.1 ASX Market Announcement Appendix 4C & Quarterly Business Update – March 2024 Launching our most comprehensive test and expanding into new global markets Melbourne, Australia, 30 April 2024: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C
April 23, 2024	EX-99.1	EX-99.1 Exhibit 99.1
April 23, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 23, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 23, 2024	EX-99.1	22 April 2024 Exhibit 99.1 22 April 2024 Company Announcements Office ASX Limited Dear Sir/Madam Genetic Technologies Limited Cleansing Notice under section 708A of the Corporations Act 2001 (Cth) On 19 April 2024 Genetic Technologies Limited ACN 009 212 328 (ASX: GTG; NASDAQ: GENE) (the Company) announced that it had received commitments for an aggregate of US$2 million (before expenses and costs of the issue)
April 23, 2024	EX-99.1	EX-99.1 Exhibit 99.1
April 23, 2024	EX-99.1	Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering Exhibit 99.1 Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering MELBOURNE, AUSTRALIA, April 23, 2024 / Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered of
April 23, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 23, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 22, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC T FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Austral
April 22, 2024	EX-10.2	PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Genetic Technologies Limited Exhibit 10.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Genetic Technologies Limited Warrant ADSs: [] Issuance Date: [], 2024 Initial Exercise Date: [], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon
April 22, 2024	EX-10.4	PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Genetic Technologies Limited Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 22, 2024	EX-99.1	Genetic Technologies Announces $2 Million Registered Direct Offering Exhibit 99.1 Genetic Technologies Announces $2 Million Registered Direct Offering MELBOURNE , Australia, April 19, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement
April 22, 2024	424B5	16,800,000 Ordinary Shares Represented by 560,000 American Depositary Shares Pre-Funded Warrants to Purchase up to 13,200,000 Ordinary Shares Represented by 440,000 American Depositary Shares 13,200,000 Ordinary Shares Represented by 440,000 American PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated January 4, 2024) Rule 424(b)(5) Registration No.
April 22, 2024	EX-10.3	WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Genetic Technologies Limited Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 22, 2024	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) dated as of April 18, 2024, is between Genetic Technologies Limited, an Australian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co
April 19, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 19, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 19, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
April 19, 2024	EX-99.1	Genetic Technologies Announces US$2 Million Registered Direct Offering Exhibit 99.1 Genetic Technologies Announces US$2 Million Registered Direct Offering MELBOURNE, AUSTRALIA, April 19, 2024 / Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase
April 17, 2024	EX-99.1	- END - Authorised for release by the Board of Directors. Exhibit 99.1 New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes Melbourne, Australia, April 17, 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its high
April 17, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 17, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 17, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
April 11, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 11, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 11, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
April 11, 2024	EX-99.1	GTG to pilot GeneType in Breast Screen centres across the U.S. Exhibit 99.1 ASX Market Announcement GTG to pilot GeneType in Breast Screen centres across the U.S. Melbourne, Australia, 11 April 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centre
April 8, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 8, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 8, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
April 8, 2024	EX-99.1	EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”. Exhibit 99.1 EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”. Melbourne, Australia, April 8, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce an innovative partnership between GTG, and Humanise Health launching a “Know
March 26, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 26, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 26, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 26, 2024	EX-99.1	GTG Secures Short Term Loan Facility with Radium Capital Exhibit 99.1 GTG Secures Short Term Loan Facility with Radium Capital Melbourne, Australia, 26 March 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce that the Company has secured a short-term loan facility with Radium Capital. GTG received $600k on 25 March 2024. T
March 25, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 25, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 25, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 25, 2024	EX-99.1	EX-99.1 Exhibit 99.1
March 22, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 20, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 20, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 22, 2024	EX-99.1	GTG to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare Exhibit 99.1 ASX Market Announcement GTG to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare Melbourne, Australia, 22 March 2024: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’
March 21, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 20, 2024 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 20, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 21, 2024	EX-99.1	EX-99.1 Exhibit 99.1
March 7, 2024	EX-99.1	Appendix 3Y Change of Director’s Interest Notice Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 We
March 7, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 6, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 6, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
February 26, 2024	EX-99.1	31 December 2023 Exhibit 99.1 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2023 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market Revenue for ordinary activities Down 5 % to $ 3,958,682 Loss after tax (from ordinary activities) for the period Up 18 % to
February 26, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 26, 2024 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 26, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 20, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 20, 2024 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 20, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 20, 2024	EX-99.1	EX-99.1 Exhibit 99.1
February 15, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 15, 2024 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 15, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 15, 2024	EX-99.1	EX-99.1 Exhibit 99.1
February 14, 2024	SC 13G/A	GNTLF / Genetic Technologies Limited / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 37185R406 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Genetic Technologies Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 37185R406 (CUSIP Number) De
February 7, 2024	EX-99.1	EX-99.1 Exhibit 99.1
February 7, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2024 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 31, 2024	EX-99.1	Appendix 4C & Quarterly Business Update – December 2023 Launching our most comprehensive test and expanding into new global markets Exhibit 99.1 Appendix 4C & Quarterly Business Update – December 2023 Launching our most comprehensive test and expanding into new global markets Melbourne, Australia, 31 January 2024: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly busin
January 31, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 31, 2024 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 31, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 9, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 09, 2024 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 09, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 9, 2024	EX-99.1	Resignation of Chief Financial Officer & Company Secretary Exhibit 99.1 Resignation of Chief Financial Officer & Company Secretary Melbourne, Australia, 8 January 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease advises that Mr Tony Di Pietro has provided his notice of resignation as Chief Financial Officer (CFO) and Company Secretary of the Compa
January 5, 2024	EX-99.1	Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement Melbourne, Australia, 5 January 2024 (Global Newswire): Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company
January 5, 2024	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 05, 2024 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 05, 2024 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 2, 2024	CORRESP	Genetic Technologies Limited 60-66 Hanover Street Fitzroy, Victoria, 3065, Australia Genetic Technologies Limited 60-66 Hanover Street Fitzroy, Victoria, 3065, Australia January 2, 2024 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
December 28, 2023	EX-99.1	EX-99.1 Exhibit 99.1
December 28, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 28, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 28, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 27, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 27, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 27, 2023	EX-99.1	Change of Directors Interest following Share Consolidation and Performance Rights Expiry Exhibit 99.1 Change of Directors Interest following Share Consolidation and Performance Rights Expiry Melbourne, Australia, 27 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, lodges four (4) updated Appendix 3Y – Change of Directors Interest notice. Please see the Appendix 3Y’s th
December 20, 2023	F-3	As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No.
December 20, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form F-3 (Form Type) Genetic Technologies Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Genetic Technologies Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares (5) Fees to Be Paid Equity Preference shares Fees to Be Paid Other Warrants Fees to Be Paid Other Units Fees to Be Paid Unallocated (Universal) Shelf Unallocated (Universal) Shelf 457(o) (2) (3) $ 75,000,000 0.
December 19, 2023	EX-99.1	Receipt of R&D Tax Incentive Refund Exhibit 99.1 ASX Market Announcement Receipt of R&D Tax Incentive Refund Melbourne, Australia, 18 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to advise that the Company has received $1.75m from the federal government’s Research and Development (R&D) Tax Incentive pr
December 19, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 19, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 19, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 12, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 12, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 12, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 12, 2023	EX-99.1	Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change Exhibit 99.1 Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change Melbourne, Australia, 12 December 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect: (i) a share consolidation of its ordinary shares (the “Shares”) of
December 7, 2023	EX-99.1	Authorised for release by the Board of Genetic Technologies Limited Exhibit 99.1 ASX Market Announcement NASDAQ Confirms First Trading Date of Consolidated ADS Melbourne, Australia, 7 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that the NASDAQ have now confirmed that 14 December 2023 will be th
December 7, 2023	424B3	THE BANK OF NEW YORK AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES WITHOUT PAR VALUE OF GENETIC TECHNOLOGIES LIMITED (ACN 009 212 328) (INCORPORATED UNDER THE LAWS OF THE STATE OF WESTERN AUSTRALIA, THE COMMONWEALTH OF AUSTRALIA) Rule 424(b)(3) File no. 333-183861 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from six hundred shares to thirty shares, and to amend the effective date to December 14, 2023. Exhibit A to Deposit Agreement AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents thirty (30) deposite
December 7, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 07, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 07, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 6, 2023	EX-99.1	Authorised for release by the Board of Genetic Technologies Limited Exhibit 99.1 ASX Market Announcement Updated Share Consolidation Timetable Melbourne, Australia, 6 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that there has been a further change to the timetable for the implementation of the
December 6, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 05, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 05, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
December 4, 2023	424B3	THE BANK OF NEW YORK AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES WITHOUT PAR VALUE OF GENETIC TECHNOLOGIES LIMITED (ACN 009 212 328) (INCORPORATED UNDER THE LAWS OF THE STATE OF WESTERN AUSTRALIA, THE COMMONWEALTH OF AUSTRALIA) Rule 424(b)(3) File no. 333-183861 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from six hundred shares to thirty shares, and to amend the effective date to December 11, 2023. Exhibit A to Deposit Agreement AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents thirty (30) deposite
December 1, 2023	EX-99.1	Authorised for release by the Board of Genetic Technologies Limited Exhibit 99.1 Change to Share Consolidation Timetable Melbourne, Australia, 1 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that there has been a change to the timetable for the implementation of the shareholder approved 100:1 sha
December 1, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 01, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 01, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 30, 2023	424B3	THE BANK OF NEW YORK AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES WITHOUT PAR VALUE OF GENETIC TECHNOLOGIES LIMITED (ACN 009 212 328) (INCORPORATED UNDER THE LAWS OF THE STATE OF WESTERN AUSTRALIA, THE COMMONWEALTH OF AUSTRALIA) Rule 424(b)(3) File no. 333-183861 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from six hundred shares to thirty shares, effective December 4, 2023. Exhibit A to Deposit Agreement AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents thirty (30) deposited Shares) THE BANK OF NEW
November 24, 2023	EX-99.1	EX-99.1 Exhibit 99.1
November 24, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 24, 2023	EX-99.1	EX-99.1 Exhibit 99.1
November 24, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 21, 2023	EX-99.1	Proposed Change to Timetable for Resolution 5 Exhibit 99.1 Proposed Change to Timetable for Resolution 5 Melbourne, Australia, 21 November 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, wishes to advise shareholders that there is a change to the indicative timetable for the implementation of a proposed share conso
November 21, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 21, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 21, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
October 30, 2023	EX-99.60	Appendix 4C & Quarterly Business Update – September 2023 Partnership with Gold Coast Private Hospital, Expanded Multi-Test for Australian Market and Commercial Partner for MRFF Grant Exhibit 99.60 Appendix 4C & Quarterly Business Update – September 2023 Partnership with Gold Coast Private Hospital, Expanded Multi-Test for Australian Market and Commercial Partner for MRFF Grant Melbourne, Australia, 30 October 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious di
October 30, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 30, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 30, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
September 27, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 27, 2023 Commission File Number 0-51504 GENETIC TECHN FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (
September 27, 2023	EX-99.1	Genetype and Gold Coast Private Hospital Announce Precision Medicine Pilot Exhibit 99.1 ASX Market Announcement Genetype and Gold Coast Private Hospital Announce Precision Medicine Pilot Melbourne, Australia, 27 September 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of
September 11, 2023	EX-99.1	MRFF Grant names GTG as sole Industry Partner Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice Exhibit 99.1 MRFF Grant names GTG as sole Industry Partner Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice Melbourne, Australia, 11 September 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomic
September 11, 2023	EX-99.1	geneType Granted Approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia Exhibit 99.1 geneType Granted Approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia Melbourne, Australia, 11 September 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the expanded geneType Multi-Risk Test is now available to order in A
September 11, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 11, 2023 Commission File Number 0-51504 GENETIC TECHN FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 11, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (
September 11, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 11, 2023 Commission File Number 0-51504 GENETIC TECHN FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 11, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (
August 31, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated August 31, 2023 Commission File Number 0-51504 GENETIC TECHNOLO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated August 31, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Add
August 31, 2023	EX-99.1	Corporate Governance Exhibit 99.1 Genetic Technologies Limited Corporate Governance CORPORATE GOVERNANCE STATEMENT INTRODUCTION The Company and its controlled entities together are referred to as the “Group” in this statement. Genetic Technologies Limited and its Board are committed to achieving and demonstrating the highest standards of corporate governance. The Company’s corporate governance policies and practices a
August 30, 2023	EX-15.2	Auditor’s independence declaration (Page 1 of 1) for ASX - This page has purposefully been left blank Exhibit 15.2 Auditor’s independence declaration (Page 1 of 1) for ASX - This page has purposefully been left blank 1
August 30, 2023	EX-99.1	Annual Results – Momentum Building on our Commercial Plans Exhibit 99.1 Annual Results – Momentum Building on our Commercial Plans Melbourne, Australia, 30 August 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023. GTG has had an exciting period of commercial growt
August 30, 2023	EX-12.01	SARBANES-OXLEY SECTION 302(a) CERTIFICATION Exhibit 12.01 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Simon Morriss, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements w
August 30, 2023	EX-12.02	SARBANES-OXLEY SECTION 302(a) CERTIFICATION Exhibit 12.02 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Tony Di Pietro, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
August 30, 2023	EX-13.02	CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.02 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tony Di Pietro, Chief Financial Officer of t
August 30, 2023	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.
August 30, 2023	EX-15.3	Independent Auditors Report (Page 1 of 5) - This page has purposefully been left blank Exhibit 15.3 Independent Auditors Report (Page 1 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 2 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 3 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 4 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 5 of
August 30, 2023	EX-4.13	Company Confidential Exhibit 4.13 Securities Trading Policy Department: Corporate COR-POL-5 Ver # 5 Active: 08-Jun-2022 Page 1 of 11 1. Purpose 1.1. This document details the policy covering restrictions on dealing in shares, options and other securities of Genetic Technologies Ltd (GTG or the Company) and its related companies (Group). 1.2. As a public company, the Company is bound by laws governing the conduct for b
August 30, 2023	EX-15.1	- End of Appendix 4E - Exhibit 15.1 Appendix 4E Preliminary final report for the twelve months to June 30, 2023 Genetic Technologies Limited ABN 17 009 212 328 1. Reporting period Report for the financial year ended June 30, 2023 Previous corresponding period is the financial year ended June 30, 2022 2. Results for announcement to the market Up/down % Amount reported for the year ended June 30, 2023 A$ Revenues from ord
August 30, 2023	EX-13.01	CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.01 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Simon Morriss, Chief Executive Officer of th
August 30, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated August 30, 2023 Commission File Number 0-51504 GENETIC TECHNOLO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated August 30, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Add
July 28, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 28, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 28, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
July 28, 2023	EX-99.60	Appendix 4C & Quarterly Business Update – June 2023 Encouraging Growth for geneType Commercial Test Volume Exhibit 99.60 Appendix 4C & Quarterly Business Update – June 2023 Encouraging Growth for geneType Commercial Test Volume Melbourne, Australia, 28 July 2023: Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly Business Update for the quarter
May 10, 2023	EX-99.1	EX-99.1 Exhibit 99.1
May 10, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 10, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 10, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addres
May 2, 2023	EX-99.1	Updated Investor Presentation and Investor Webinar Exhibit 99.1 ASX Market Announcement Updated Investor Presentation and Investor Webinar Melbourne, Australia, 2 May 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to provide shareholders with the latest Investor Presentation and invite shareholders to attend a webinar with Simo
May 2, 2023	EX-99.2	EX-99.2 Exhibit 99.2
May 2, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 2, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 2, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Address
April 28, 2023	EX-99.1	New Publication Validates geneType for Melanoma Risk Assessment Exhibit 99.1 ASX Market Announcement New Publication Validates geneType for Melanoma Risk Assessment Melbourne, Australia, 28 April 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research vali
April 28, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 28, 2023 Commission File Number 0-51504 GENETIC TECHNOLOG 6-K 1 form6-k.htm FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 28, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 30
April 27, 2023	EX-99.1	Appendix 4C & Quarterly Business Update – March 2023 Driving growth, Expanded Multi-Test Panel and Publications Validating Clinical Utility of geneType Exhibit 99.1 ASX Market Announcement Appendix 4C & Quarterly Business Update – March 2023 Driving growth, Expanded Multi-Test Panel and Publications Validating Clinical Utility of geneType Melbourne, Australia, 27 April 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, re
April 27, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 27, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOG 6-K 1 form6-k.htm FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 27, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 30
March 27, 2023	EX-99.69	GeneType Multi-Test Panel Expanded: Inclusion of 3 New Diseases Exhibit 99.69 GeneType Multi-Test Panel Expanded: Inclusion of 3 New Diseases Melbourne, Australia, 27 March 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the initiation of phase 2 of the rollout plan for the geneType Multi-Test. The expanded panel now includes
March 13, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 13, 2023 Commission File Number 0-51504 GENETIC TECHNOLOG FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated March 13, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addr
March 13, 2023	EX-99.69	Back-to-back Studies Validate geneType Breast Cancer Risk Test Exhibit 99.69 Back-to-back Studies Validate geneType Breast Cancer Risk Test Melbourne, Australia, 13 March 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessmen
February 27, 2023	EX-99.68	31 December Exhibit 99.68 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2022 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2022 Previous period: 31 December 2021 Results for announcement to the market $ Revenue for ordinary activities Up 103 % to 4,153,947 Net loss after tax (from ordinary activities) for the period attrib
February 27, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2023 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 13, 2023	SC 13G	GENE / Genetic Technologies Ltd. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 37185R307 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Genetic Technologies Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 37185R307 (CUSIP Number) Feb
February 9, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 9, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 9, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 9, 2023	EX-99.67	20230209 – Business Update February 2023 FINAL Exhibit 99.67
February 9, 2023	EX-99.66	New Publication Highlights geneType’s ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification Exhibit 99.66 ASX Market Announcement New Publication Highlights geneType’s ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification Melbourne, Australia, 9 February 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new
February 9, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 9, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 9, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 7, 2023	424B5	2,307,693,000 Ordinary Shares Represented by 3,846,155 American Depositary Shares PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated March 23, 2020) Rule 424(b)(5) Registration No.
February 7, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 7, 2023	EX-99.65	Genetic Technologies Announces Closing of $5 Million Registered Direct Offering Exhibit 99.65 Genetic Technologies Announces Closing of $5 Million Registered Direct Offering MELBOURNE, AUSTRALIA, February 7, 2023 / GLOBE NEWSWIRE / Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously annou
February 7, 2023	6-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2023 Commission File Number 0-51504 GENETIC TECHNOL U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 7, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 7, 2023	EX-10.1	Securities Purchase Agreement dated February 3, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) dated as of February 3, 2023, is between Genetic Technologies Limited, an Australian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
February 7, 2023	EX-99.1	Genetic Technologies Announces $5 Million Registered Direct Offering Exhibit 99.1 Genetic Technologies Announces $5 Million Registered Direct Offering February 03, 2023 08:35 ET \| Source: Genetic Technologies Ltd MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, toda
February 6, 2023	EX-99.64	Supplementary Announcement - Comprehensive Risk Test for Breast & Ovarian Cancer Exhibit 99.64 ASX Market Announcement Supplementary Announcement - Comprehensive Risk Test for Breast & Ovarian Cancer Melbourne, Australia, 6 February 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, provides further information at the request of the ASX in regards to the announcement rel
February 6, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 6, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 6, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 3, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 3, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 3, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 3, 2023	EX-99.63	Genetic Technologies Announces $5 Million Registered Direct Offering Exhibit 99.63 Genetic Technologies Announces $5 Million Registered Direct Offering MELBOURNE, AUSTRALIA, February 3, 2023 / GLOBE NEWSWIRE / Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into definitive agreements
February 3, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 3, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 3, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 3, 2023	EX-99.62	GTG to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer Exhibit 99.62 ASX Market Announcement GTG to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer Melbourne, Australia, 3 February 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessme
February 1, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 1, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 1, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
February 1, 2023	EX-99.61	GTG to form Strategic Alliance with global testing leader QIAGEN Exhibit 99.61 ASX Market Announcement GTG to form Strategic Alliance with global testing leader QIAGEN Melbourne, Australia, 1 February, 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a
January 30, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 30, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 30, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 30, 2023	EX-99.60	Authorized for release by the Board of Genetic Technologies Limited Exhibit 99.60 Melbourne, Australia, 30 January 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December 2022 (Q2 FY23). Highlights: ● Qtr 2 Receipts from customers were A$2.4 million, up 15% compared to prior q
January 24, 2023	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 24, 2023 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 24, 2023 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 24, 2023	EX-99.59	Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk Presented at ASCOGI Cancer Symposium Exhibit 99.59 ASX Market Announcement Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk Presented at ASCOGI Cancer Symposium Melbourne, Australia, 24 January 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation
November 28, 2022	EX-99.57	20221128 – Geneetic Technologies Limited AGM 2022 FINAL Exhibit 99.57
November 28, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 28, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 28, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 10, 2022	EX-99.56	Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease Exhibit 99.56 Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professo
November 10, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 10, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 10, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 9, 2022	EX-99.55	Genetype for Ovarian Cancer published in prestigious European Journal of Cancer Prevention Exhibit 99.55 ASX Market Announcement Genetype for Ovarian Cancer published in prestigious European Journal of Cancer Prevention Melbourne, Australia, 09 November 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation stud
November 9, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 9, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 9, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 25, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 25, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 25, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 25, 2022	EX-99.54	Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Exhibit 99.54 Melbourne, Australia, 25 October 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended 30 September 2022 (Q1 FY23). Highlights: ● Revenue from customers of A$1.93 million for the quarter, up 375% from prior correspond
October 14, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 14, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 14, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 14, 2022	EX-99.53	Bloomberg airs Genetic Technologies Business Update with CEO on RedChip Money Report ® Exhibit 99.53 Bloomberg airs Genetic Technologies Business Update with CEO on RedChip Money Report ? Melbourne, Australia, 14 October 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in guideline driven genomics-based tests in health, wellness and serious disease will be sharing a business update on The RedChip Money Report? on Bloomberg TV, this Satur
October 11, 2022	EX-99.52	Appointment of CFO and Company Secretary Exhibit 99.52 Appointment of CFO and Company Secretary Melbourne, Australia, 10 October 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to announce the appointment of experienced Chief Financial Officer, Mr Tony Di Pietro. Tony will also be appointed as Company
October 11, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 10, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 10, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant’s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
September 29, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 29, 2022 Commission File Number 0-51504 GENETIC TECHN FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated September 29, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (
September 29, 2022	EX-99.51	Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer EX-99.51 2 ex99-51.htm Exhibit 99.51 Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer Melbourne, Australia, 29 September 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publ
August 30, 2022	EX-15.1	Consent of Grant Thornton Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-237152) of Genetic Technologies Limited of our report dated August 30, 2022 relating to the financial statements, which appears in this Form 20-F. /s/ Grant Thornton Audit Pty Ltd Melbourne, Australia August 30, 2022
August 30, 2022	EX-15.4	Auditor’s Independence Declaration Exhibit 15.4 Auditor’s independence declaration (Page 1 of 1) for ASX - This page has purposefully been left blank
August 30, 2022	EX-13.02	Section 906 Certification of the Chief Financial Officer Exhibit 13.02 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the “Company”) on Form 20-F for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mike Tonroe, Chief Financial Officer of the
August 30, 2022	EX-4.12	Sale of Business Agreement dated July 14, 2022 Exhibit 4.12 CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS NOT MATERIAL AND DISCLOSURE THEREOF WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. ASSET PURCHASE AGREEMENT This Asset Purchase Agreement is dated 12th May 2022 (Effective Date) by and between G
August 30, 2022	EX-15.3	Appendix 4E Exhibit 15.3 Appendix 4E Preliminary final report for the twelve months to June 30, 2022 Genetic Technologies Limited ABN 17 009 212 328 1. Reporting period Report for the financial year ended June 30, 2022 Previous corresponding period is the financial year ended June 30, 2021 2. Results for announcement to the market Up/down % Amount reported for the year ended June 30, 2022 $ Revenues from ordi
August 30, 2022	EX-12.01	Section 302 Certification of the Chief Executive Officer Exhibit 12.01 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Simon Morriss, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements w
August 30, 2022	EX-15.2	Consent of PricewaterhouseCoopers Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-237152) of Genetic Technologies Limited of our report dated October 22, 2020 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Melbourne, Australia August 30, 2022
August 30, 2022	EX-12.02	Section 302 Certification of the Chief Financial Officer Exhibit 12.02 SARBANES-OXLEY SECTION 302(a) CERTIFICATION I, Mike Tonroe, certify that: 1. I have reviewed this annual report on Form 20-F of Genetic Technologies Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements wer
August 30, 2022	EX-13.01	Section 906 Certification of the Chief Executive Officer Exhibit 13.01 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetic Technologies Limited (the ?Company?) on Form 20-F for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Simon Morriss, Chief Executive Officer of th
August 30, 2022	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.
August 30, 2022	EX-15.5	Independent Auditor’s Report Exhibit 15.5 Independent Auditors Report (Page 1 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 2 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 3 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 4 of 5) - This page has purposefully been left blank Independent Auditors Report (Page 5 of
July 28, 2022	EX-99.50	Q4 FY22 Results Milestones and Growth EX-99.50 2 ex99-50.htm Exhibit 99.50 ASX Market Announcement Q4 FY22 Results Milestones and Growth Melbourne, Australia, 28 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease provides its cashflow results for the quarter ended 30 June 2022 (Q4 FY22). Financial Highlights: ● Cash receipt
July 28, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 28, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 28, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
July 18, 2022	EX-99.49	GeneType risk test implemented in 9 Siles Health Obstetrics and Gynaecology clinics treating over 15,000 patients annually EX-99.49 2 ex99-49.htm Exhibit 99.49 ASX Market Announcement GeneType risk test implemented in 9 Siles Health Obstetrics and Gynaecology clinics treating over 15,000 patients annually Melbourne, Australia, 18 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce th
July 18, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 18, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 18, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
July 14, 2022	EX-99.48	Completion of AffinityDNA Acquisition expanding global direct-to-consumer business Exhibit 99.48 ASX Market Announcement Completion of AffinityDNA Acquisition expanding global direct-to-consumer business Melbourne, Australia, 14 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the acquisition of the direct-to-consumer e
July 14, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 14, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 14, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
July 5, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 5, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 5, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addres
July 5, 2022	EX-99.46	Mike Tonroe - Company Secretary Resignation EX-99.46 2 ex99-46.htm Exhibit 99.46 ASX Market Announcement Mike Tonroe - Company Secretary Resignation Melbourne, Australia, 4 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease advises that Mr Michael Tonroe has resigned as Chief Financial Officer (CFO) and Company Secretary of the C
July 5, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 5, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 5, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addres
July 5, 2022	EX-99.47	EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage Exhbit 99.47 EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage Melbourne, Australia, 5 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company?s recently acquired, EasyDNA, has embarked on a significant expansion
July 1, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 1, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated July 1, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addres
July 1, 2022	EX-99.45	GeneType Risk Assessment Test onboarding in 16 clinics EX-99.45 2 ex99-45.htm Exhibit 99.45 ASX Market Announcement GeneType Risk Assessment Test onboarding in 16 clinics Melbourne, Australia, 30 June 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company has commenced initial implementation of its geneType Risk
June 16, 2022	EX-99.44	Transformational pathway to US Payer system; Attributing Potential US$1.4 billion health and economic benefit from geneType Breast Cancer Risk Assessment Test Exhibit 99.44 ASX Market Announcement Transformational pathway to US Payer system; Attributing Potential US$1.4 billion health and economic benefit from geneType Breast Cancer Risk Assessment Test Melbourne, Australia, 15 June 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in genomics-based tests in health, wellness and serious disease is delighted t
June 16, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated June 16, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated June 16, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
May 16, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 16, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIE FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated May 16, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addres
May 16, 2022	EX-99.43	-END- EX-99.43 2 ex99-43.htm Exhibit 99.43 ASX Market Announcement Acquisition of global direct to consumer ecommerce business Melbourne, Australia, 16 May 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce b
April 8, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 8, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGI FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated April 8, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Addre
April 8, 2022	EX-99.42	Genetic Technologies Q3 FY’22 Results Regulatory approvals, patent granted and revenue growth Exhibit 99.42 Genetic Technologies Q3 FY?22 Results Regulatory approvals, patent granted and revenue growth Melbourne, Australia, 8 April 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in genomics-based tests in health, wellness and serious disease provides its results for the quarter ended 31 March 2022 (?Quarter?). Highlights ? Year to date growth
February 24, 2022	EX-99.40	20220224 – Genetic Technologies Limited 1H FY22 Results FINAL Exhibit 99.40
February 24, 2022	EX-99.41	Up Exhibit 99.41 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2021 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for announcement to the market $ Revenue for ordinary activities Up 12,379 % to 2,051,016 Net loss after tax (from ordinary activities) for the period att
February 24, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 24, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 24, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 23, 2022	EX-99.39	US Patent Office Grants Patent for COVID-19 Risk Test Exhibit 99.39 ASX Market Announcement US Patent Office Grants Patent for COVID-19 Risk Test Melbourne, Australia, 23 February 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a sever
February 23, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 23, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 23, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 22, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 21, 2022 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated February 21, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
February 22, 2022	EX-99.38	20220221 – GeneType Multi-Test Approved for Commercial Release FINAL Exhibit 99.38
January 21, 2022	EX-99.37	20220121 - GTG Quarterly Investor Presentation FINAL Exhibit 99.37
January 21, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 21, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 21, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 19, 2022	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 19, 2022 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated January 19, 2022 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
January 19, 2022	EX-99.36	Genetic Technologies Q2 FY22 Cash Flow Results Q2 momentum sets the stage for a strong FY22 Exhibit 99.36 Genetic Technologies Q2 FY22 Cash Flow Results Q2 momentum sets the stage for a strong FY22 Melbourne, Australia, 19 January 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?, ?geneType?), a diversified Genomics and AI driven preventative health business provides its results for the quarter ended 31 December 2021. Highlights: ? Solid cash balance of A$13.5
December 21, 2021	EX-99.35	Momentum building: Cash receipts +112% for Q2 FY22 to A$1.8m Exhibit 99.35 Momentum building: Cash receipts +112% for Q2 FY22 to A$1.8m Melbourne, Australia, 21 December 2021: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?, ?geneType?), a global leader in genomics-based tests in health, wellness and serious disease provides the following business update: ? Forecast 2QFY221 cash receipts +112% versus the prior quarter (1QFY22) to A$1.
December 21, 2021	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 21, 2021 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated December 21, 2021 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 24, 2021	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2021 Commission File Number 0-51504 GENETIC TECHNO FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated November 24, 2021 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (A
November 24, 2021	EX-99.34	20211124 - Genetic Technologies Limited AGM 2021 FINAL Exhibit 99.34
October 26, 2021	EX-99.33	20211026 - GTG Quarterly Business Update FINAL Exhibit 99.33
October 26, 2021	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 26, 2021 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 26, 2021 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 25, 2021	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 25, 2021 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 25, 2021 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 25, 2021	EX-99.32	Genetic Technologies Q1 FY22 Results Material Increase in Cash Receipts Exhibit 99.32 Genetic Technologies Q1 FY22 Results Material Increase in Cash Receipts Melbourne, Australia, 25 October 2021: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ?Company?, ?GTG?), a global leader in Genomics based tests in health, wellness and serious disease provides its results for the quarter ended 30 September 2021. Highlights ? Cash receipts of A$850k, a material increase on
October 22, 2021	6-K	FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 22, 2021 Commission File Number 0-51504 GENETIC TECHNOL FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 dated October 22, 2021 Commission File Number 0-51504 GENETIC TECHNOLOGIES LIMITED (Exact Name as Specified in its Charter) N/A (Translation of Registrant?s Name) 60-66 Hanover Street Fitzroy Victoria 3065 Australia (Ad
October 22, 2021	EX-99.31	Genetic Technologies Limited ACN 009 212 328 Notice of Annual General Meeting Venue: Virtual Meeting Date: Wednesday 24 November 2021 Time: Commencing at 9:00am (AEDT) EX-99.31 2 ex99-31.htm Exhibit 99.31 Genetic Technologies Limited ACN 009 212 328 Notice of Annual General Meeting Venue: Virtual Meeting Date: Wednesday 24 November 2021 Time: Commencing at 9:00am (AEDT) Contents Page Key dates 1 Notice of General Meeting 2 Proxy Appointment, Voting and Meeting Instructions 5 Explanatory Statement 6 Key dates The key dates for the Annual General Meeting (AGM) are

GENE / Genetic Technologies Limited - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)